Showing results (2291-2300 of 2,381) with videos related to

Sort By:
Pageof 239
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Nucleic Acids Research|March 21, 2023
CAF-1 deposits newly synthesized histones during DNA replication using distinct mechanisms on the leading and lagging strandsClément Rouillon, Bruna V Eckhardt, Leonie Kollenstart, et al.
Brain, Behavior, and Immunity|December 24, 2023
Microglial TNFR2 signaling regulates the inflammatory response after CNS injury in a sex-specific fashionStefano Raffaele, Estrid Thougaard, Cathrine C H Laursen, et al.
Acta Neuropathologica|January 20, 2024
Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastomaRichard Drexler, Robin Khatri, Ulrich Schüller, et al.
Nature Communications|January 9, 2020
Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolismMegan M Weivoda, Chee Kian Chew, David G Monroe, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesDaniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
Scientific Reports|November 22, 2022
EEG-based grading of immune effector cell-associated neurotoxicity syndromeDaniel K Jones, Christine A Eckhardt, Haoqi Sun, et al.
Pageof 239